Midatech Pharma (Nasdaq:MTP) announced today that it extended its R&D collaboration with Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals.
Cardiff, United Kingdom-based Midatech, a drug delivery technology company focused on the biodelivery and biodistribution of medicines, initially entered into the R&D collaboration with Janssen on July 21, 2020.
On June 17, 2021, Midatech confirmed that its Q-Sphera technology — which focuses on long-acting injectables using proprietary 3D printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics — successfully encapsulated a proprietary Janssen experimental large-molecule medicine and preserved its functional integrity.
According to a news release, Midatech believes that no other commercial or academic organization has successfully delivered any such experimental medicine over extended periods using methods capable of commercial scaling.
On the back of the successful program (MTX213), the companies have agreed to extend the collaboration to include another large molecule, with a focus on maximizing drug loading and optimizing in vitro duration of release for the undisclosed Janssen experimental molecule with Midatech’s Q-Sphera technology.
“We look forward to working with Janssen and the application of our technology specific to this new API,” Midatech CSO Dmitry Zamoryakhin said in the release.
